natgillin/translations-raw huggingface dataset:
Patients with unstable angina, angina with sexual intercourse, or congestive heart failure categorised as New York Heart Association Class 2 or greater.
> 170/100 mmHg) med mirovalno fazo; bolnikih z nestabilno angino pektoris, angino pektoris, ki se pojavlja med spolnimi odnosi, ali kongestivnim srčnim popuščanjem, ki spada v razred 2 ali višje po klasifikaciji Newyorškega združenja za srce.
Patients with unstable cardiopulmonary status
Bolniki z nestabilnim kardiopulmonalnim stanjem
Patients with urea cycle disorders are not able to get rid of waste nitrogen from the body because they lack some liver enzymes.
Bolniki z motnjami ciklusa sečnine ne morejo odvajati odpadnega dušika iz telesa, ker jim primanjkuje nekaterih jetrnih encimov.
Patients with very low initial haemoglobin (< 6 g/dl or < 3.75 mmol/l) may require higher maintenance doses than patients whose initial anaemia is less severe (> 8 g/dl or > 5 mmol/l).
Bolniki z zelo majhno začetno koncentracijo hemoglobina (< 6 g/dl ali < 3,75 mmol/l) lahko potrebujejo večje vzdrževalne odmerke kot bolniki z blažjo začetno anemijo (> 8 g/dl ali > 5 mmol/l).
Patients with visceral disease, patients with a history of mild to moderate heart failure (NYHA Class 1 or 2), and patients taking medications associated with lowering the seizure threshold were allowed.
Sodelovanje bolnikov z visceralno boleznijo, bolnikov z blagim do zmernim srčnim popuščanjem (razred 1 ali 2 po NYHA) v anamnezi in bolnikov, ki so jemali zdravila, povezana z nižanjem praga za konvulzije, je bilo dovoljeno.
Patients with visceral metastases and malignant lymphadenopathy exceeding 3 cm were excluded.
Bolniki z metastazami v notranjih organih in maligno limfadenopatijo, večjo kot 3 cm, so bili izključeni.
Patients with visual hallucinations
Bolniki z vizualnimi halucinacijami
Patients with wet AMD will be treated with one injection per month for three consecutive doses, followed by one injection every two months.
Bolniki z vlažno starostno degeneracijo rumene pege bodo zdravljeni z eno injekcijo na mesec tri zaporedne mesece, nato pa se bo zdravljenje nadaljevalo z eno injekcijo vsaka dva meseca.
Patients with wheat allergy (different from coeliac disease) should not take this medicinal product.
Pacienti z alergijo na pšenico (ki je drugačna od celiakije) ne smejo jemati tega zdravila.
Patients with WHO FC II and III had a mean baseline 6MWD of 353 metres.
Bolniki v II. in III. funkcijskem razredu po SZO so imeli izhodiščno 6-minutno prehojeno razdaljo 353 metrov.
Patients with xerostomia:
Bolniki s kserostomijo:
patients with ≥ 150,000 platelets/mm3: 15 MBq/kg body weight. patients with 100,000-150,000 platelets/mm3: 11 MBq/kg The maximum dose must not exceed 1200 MBq.
bolniki s 150.000 ali več trombociti/mm3: 15 MBq/kg telesne mase bolniki z 100.000 – 150.000 trombociti/mm3: 11 MBq/kg Največji odmerek ne sme preseči 1200 MBq.
patients with ≥ 150,000 platelets/mm³: 15 MBq/kg up to a maximum of 1200 MBq for patients with less than 150,000 platelets per mm³ see section ‘4.4’
bolniki s 150.000 ali več trombociti/mm3: 15 MBq/kg do največ 1200 MBq za bolnike z manj kot 150.000 trombociti na mm³ glejte poglavje 4.4
Patients with ≥3 Events
bolniki z ≥ 3 dogodki
Patients without a gallbladder ( e.g. due to cholecystectomy or agenesis).
Bolniki brez žolčnika (na primer zaradi holecistektomije ali agenezije).
Patients without a history of sulphonamide allergy may also be at risk for serious skin reactions.
Tudi pri bolnikih brez anamneze alergije na sulfonamide se lahko pojavi tveganje za resne kožne reakcije.
Patients without at least a minor erythroid response within 4 months of therapy initiation, demonstrated by at least a 50% reduction in transfusion requirements or, if not transfused, a 1g/dl rise in haemoglobin, should discontinue lenalidomide treatment.
Bolnikom brez vsaj manjšega eritroidnega odziva v 4 mesecih po uvedbi zdravljenja, ki se dokaže z vsaj 50 % zmanjšanjem potreb po transfuzijah ali če ne dobivajo transfuzij, s porastom hemoglobina za 1g/dl, ukinite zdravljenje z lenalidomidom.
Patients without cirrhosis
bolniki s cirozo
Patients without cirrhosis N = 155
Bolniki brez ciroze N = 155
Patients without identified mutation, n (%)
Bolniki brez identificirane mutacije, n (%)
Patients without Prior Cisplatin Chemoradiotherapy
Bolnice brez predhodne kemoradioterapije s cisplatinom
Patients without Prior Cisplatin Chemoradiotherapy
Bolnice brez predhodne kemoterapije s cisplatinom
Patients without prior cisplatin chemoradiotherapy
Bolniki brez predhodne cisplatinske kemoradioterapije
Patients without RET mutation may have a decreased benefit from vandetanib treatment and the benefit/risk balance for this group of patients may therefore differ from that of the group with RET mutations.
Pri bolnikih brez mutacije RET je lahko korist zdravljenja z vandetanibom manjša in razmerje korist/tveganje se za to skupino bolnikov lahko razlikuje od tistega za skupino bolnikov z mutacijo RET.
Patients without SVR
Bolniki brez SVR
Patients without this disease may use sildenafil for impotence (erectile dysfunction) under their doctor’s supervision (see the section on Other medicines and Norvir);
Bolniki brez te bolezni lahko sildenafil uporabljajo za impotenco (erektilno disfunkcijo) pod nadzorom svojega zdravnika (glejte poglavje Druga zdravila in zdravilo Norvir),
Patients ≥ 75 years of age have greater sensitivity to bleeding and higher exposure to the active metabolite of prasugrel (see sections 4.4, 4.8, 5.1 and 5.2).
Bolniki ≥ 75 let so bolj nagnjeni h krvavitvi in bolj izpostavljeni aktivnemu presnovku prasugrela (glejte poglavja 4.4, 4.8, 5.1 in 5.2).
Patients ≥ 75 years were at increased risk of bleeding, including fatal (see sections 4.2, 4.4, and 4.8).
≥ 75 let so imeli večje tveganje za krvavitev, vključno s smrtno (glejte poglavja 4.2, 4.4 in 4.8).
Patients ≥65 years were more likely to experience serious adverse events (SAEs) and experience AEs leading to discontinuation of cobimetinib than those 65 years.
Bolniki, stari 65 let ali več, so imeli večjo verjetnost za resne neželene učinke in za neželene učinke, ki so povzročili prenehanje zdravljenja s kobimetinibom, kot bolniki, mlajši od 65 let.
Patients 60 years of age treated with capecitabine plus docetaxel also had more early withdrawals from treatment due to adverse reactions compared to patients <60 years of age.
Bolniki, stari 60 let ali več, zdravljeni s kapecitabinom in docetakselom, so v primerjavi z bolniki, mlajšimi od 60 let, zaradi neželenih učinkov v večjem številu zgodaj prekinili zdravljenje.
patients, 48.2% (253 of 525) had renal impairment (36.4% mild, 9.5% moderate and 2.3% severe).
Med bolniki z zaporo mrežnične vene je imelo okvaro ledvic 48,2 % (253 od 525) bolnikov (36,4 % blago, 9,5 % zmerno in 2,3 % hudo).
Patients, carers and doctors need to be aware that Tysabri can be associated with infections, including the brain infection PML.
Bolniki, njihovi negovalci in zdravniki se morajo zavedati, da je zdravilo Tysabri lahko povezano z okužbami, vključno z okužbo možganov, imenovano PML (progresivna multifokalna levkoencefalopatija).
Patients, especially children and adolescents, should be closely monitored for the behavioural changes described above.
Bolnike, še posebej otroke in mladostnike je treba skrbno spremljati glede pojava sprememb v vedenju, ki so opisane zgoraj.
Patients, especially children and adolescents, should be closely monitored for the behavioural changes described above.
Bolnike, še posebej otroke in mladostnike, je treba skrbno spremljati glede pojava sprememb v vedenju, ki so opisane zgoraj.
Patients, especially children, with risk factors for acute pancreatitis (e.g., recent chemotherapy, haematopoietic stem cell transplantation (HSCT)), should be monitored closely during voriconazole treatment.
Bolnike, še posebej otroke, z dejavniki tveganja za akutni pankreatitis (npr. nedavna kemoterapija, presaditev matičnih krvotvornih celic [HSCT – Haematopoietic Stem Cell Transplantation]) je treba med zdravljenjem z vorikonazolom skrbno nadzorovati.
Patients, especially children, with risk factors for acute pancreatitis (e.g., recent chemotherapy, haematopoietic stem cell transplantation [HSCT]), should be monitored closely during VFEND treatment.
Bolnike, še posebej otroke, z dejavniki tveganja za akutni pankreatitis (npr. nedavna kemoterapija, presaditev matičnih krvotvornih celic [HSCT – Haematopoietic Stem Cell Transplantation]) je treba med zdravljenjem z zdravilom VFEND skrbno nadzorovati.
Patients, especially children, with risk factors for acute pancreatitis (e.g., recent chemotherapy, haematopoietic stem cell transplantation [HSCT]), should be monitored closely during Voriconazole Accord treatment.
Bolnike, še posebej otroke, z dejavniki tveganja za akutni pankreatitis (npr. nedavna kemoterapija, presaditev matičnih krvotvornih celic [HSCT – Haematopoietic Stem Cell Transplantation]) je treba med zdravljenjem z zdravilom Vorikonazol Accord skrbno nadzorovati.
Patients, especially elderly patients and those receiving diuretic therapy, should be appropriately hydrated prior to administration of Aclasta.
Pred odmerjanjem zdravila Aclasta morajo biti bolniki, zlasti starejši in tisti, ki jemljejo diuretike, primerno hidrirani.
Patients, especially elderly patients and those receiving diuretic therapy, should be appropriately hydrated prior to administration of Zoledronic acid Teva Generics.
Pred odmerjanjem zoledronske kisline morajo biti bolniki, zlasti starejši in tisti, ki jemljejo diuretike, primerno hidrirani.
Patients, especially elderly patients and those receiving diuretic therapy, should be appropriately hydrated prior to administration of Zoledronic acid Teva Pharma.
Pred odmerjanjem zdravila Zoledronska kislina Teva Pharma morajo biti bolniki, zlasti starejši in tisti, ki jemljejo diuretike, primerno hidrirani.
Patients, especially elderly patients and those receiving diuretic therapy, should be appropriately hydrated prior to administration of zoledronic acid.
Pred dajanjem zoledronske kisline morajo biti bolniki, zlasti starejši in tisti, ki jemljejo diuretike, primerno hidrirani.
Patients, especially elderly patients and those receiving diuretic therapy, should be appropriately hydrated prior to administration of zoledronic acid.
Pred odmerjanjem zoledronske kisline morajo biti bolniki, zlasti starejši in tisti, ki jemljejo diuretike, primerno hidrirani.
Patients, in whom a first treatment course did not lead to complete clearance of all Aks in the treatment area after 8 weeks, were randomised to another treatment course with Picato or vehicle.
Bolniki, pri katerih s prvim ciklom zdravljenja po 8 tednih niso dosegli popolne ozdravitve vseh aktiničnih keratoz na zdravljenem predelu, so bili randomizirani na dodaten cikel zdravljenja z zdravilom Picato ali vehiklom.
Patients, n
Bolniki, n
Patients, who initially received placebo or 5 mg lenalidomide and did not achieve at least a minor erythroid response after 16 weeks of treatment were permitted to switch from placebo to 5 mg lenalidomide or continue lenalidomide treatment at higher dose (5 mg to 10 mg).
Bolniki, ki so na začetku prejemali placebo ali 5 mg lenalidomida, in niso dosegli vsaj manjšega eritroidnega odziva po 16 tednih zdravljenja, so smeli zamenjati placebo s 5 mg lenalidomida ali nadaljevati zdravljenje z večjim odmerkom lenalidomida (5 mg do 10 mg).
patients.
njim.
Patientswho developed antibodies to infliximab were more likely (approximately 2-3 fold) to develop infusion-related reactions.
Pri bolnikih, pri katerih so se pojavila protitelesa proti infliksimabu, je verjetnost za pojav z infuzijo povezanih reakcij večja (približno 2 do 3-krat).
Patients’ body weight category (kg)
Bolnikova telesna masa (kg)
Patients’ median LVEF at baseline was 65.0% (range 50% – 88%) in both groups.
Mediana LVEF bolnikov pred začetkom zdravljenja je bila 65 (razpon 5088 % v obeh skupinah).
Patients’ reminder cards will warn that the medicine must never be used in pregnant women and that women who could become pregnant must be using reliable contraception and should undergo monthly pregnancy tests.
Kartice z opozorili za bolnike bodo opozarjale na to, da se zdravilo v nobenem primeru ne sme uporabljati pri nosečnicah in da morajo ženske, ki bi lahko zanosile, uporabljati zanesljivo metodo kontracepcije ter vsak mesec opraviti test za ugotavljanje nosečnosti.
Patients’ response should be monitored when they are switching from concomitant non-inducer anti-epileptic medicinal products to enzyme inducing medicinal products and vice versa.
Odziv bolnikov je treba spremljati, ko preidejo iz sočasne uporabe antiepileptičnih zdravil, ki ne spodbujajo encima, na zdravila, ki spodbujajo encim, in obratno.
Patients’ responsibilities regarding insulin treatment as well as refill frequency and maintenance of the pump as outlined in the key messages in the patient information leaflet;
Bolnikovih odgovornostih glede zdravljenja z insulinom, pogostnosti ponovnega polnjenja in vzdrževanja črpalke, kot je orisano v ključnih sporočilih v navodilu za uporabo.
patient’s clinical and bacteriological progress5
kliničnega in bakteriološkega napredka5
patient’s daily clearance and desired
bolnikov dnevni očistek in želene
Patient’s eligibility
primernost bolnika
Patient’s events diary
Dnevnik za dogodke pri bolniku
Patient’s name:
Bolnikovo ime:
Patient’s Name: Doctor’s Name: Doctor’s Phone:
Bolnikovo ime: Zdravnikovo ime: Zdravnikova tel. št.:
Patient’s Name: Doctor’s Name: Doctor’s Phone:
Ime in priimek bolnika: Ime in priimek zdravnika: Telefonska številka zdravnika:
Patient’s previous treatment consisted either of two nucleotide reverse transcriptase inhibitors and another HIV medicine called a boosted protease inhibitor, or the medicine Atripla.
Bolniki so prej jemali bodisi dva zaviralca nukleotidne reverzne transkriptaze in še eno drugo zdravilo za zdravljenje okužbe z virusom HIV, imenovano okrepljeni zaviralec proteaze, bodisi zdravilo Atripla.
Patient’s response should be evaluated after 3 months treatment and the need for treatment continuation should be reconsidered.
Bolnikov odziv na zdravljenje moramo po 3 mesecih oceniti in presoditi, ali je treba zdravljenje nadaljevati.
Paxene 6 mg/ml concentrate for solution for infusion paclitaxel
Paxene 6 mg/ml koncentrat za raztopino za infundiranje (paklitaksel)
Paxene 6 mg/ml concentrate for solution for infusion paclitaxel
Paxene 6 mg/ml koncentrat za raztopino za infundiranje paklitaksel
Paxene 6 mg/ml concentrate for solution for infusion.
Paxene 6 mg/ml koncentrat za raztopino za infundiranje
Paxene contains polyoxyl castor oil, which can cause an allergic reaction.
Zdravilo Paxene vsebuje makrogolglicerol ricinolat, ki lahko povzroči alergijske reakcije.
Paxene contains polyoxyl castor oil, which can cause an allergic reaction.
Zdravilo Paxene vsebuje makrogolglicerol ricinolat, ki lahko povzroči alergijsko reakcijo.
Paxene has been studied in 107 patients with Kaposi’s sarcoma, 312 patients with metastatic breast cancer, 120 patients with metastatic ovarian cancer, over 900 patients with advanced ovarian cancer and over 1,000 patients with lung cancer.
Zdravilo Paxene so raziskovali pri 107 bolnikih s Kaposijevim sarkomom, 312 bolnicah z metastatskim rakom dojk, 120 bolnicah z metastatskim rakom jajčnikov, več kot 900 bolnicah z napredovalim rakom jajčnikov in več kot 1 000 bolnikih s pljučnim rakom.
Paxene is indicated for the treatment of patients with: advanced AIDS-related Kaposi’s sarcoma (AIDS-KS) who have failed prior liposomal anthracycline therapy; metastatic carcinoma of the breast (MBC) who have failed, or are not candidates for standard anthracycline-containing therapy; advanced carcinoma of the ovary (AOC) or with residual disease ( 1 cm) after initial laparotomy, in combination with cisplatin as first-line treatment; metastatic carcinoma of the ovary (MOC) after failure of platinum-containing combination therapy without taxanes as second-line treatment; non-small cell lung carcinoma (NSCLC) who are not candidates for potentially curative surgery and/or radiation therapy, in combination with cisplatin.
Zdravilo Paxene je indicirano za zdravljenje bolnikov z: napredovalim Kaposijevim sarkomom, povezanim z AIDS (AIDS-KS), pri katerih je bilo predhodno zdravljenje z antraciklini v obliki liposomov neuspešno, metastatskim karcinomom dojke (metastatic breast cancer - MBC), pri katerih je bilo standardno zdravljenje z antraciklini neuspešno ali pa tovrstno zdravljenje za njih ni primerno, napredovalim karcinomom jajčnikov (advanced carcinoma of the ovary - AOC) ali z rezidualno boleznijo (> 1 cm) po prvotni lapratomiji, v kombinaciji s cisplatinom kot zdravljenje prvega izbora, metastatskim karcinomom jajčnika (metastatic ovarian cancer - MOC) po neuspešnem kombiniranem zdravljenju s platino, ki ne vključuje taksanov zdravljenje drugega izbora, nedrobnoceličnim karcinomom pljuč (non-small cell lung carcinoma - NSCLC), ki niso kandidati za potencialno zdravilni operacijski poseg in/ali zdravljenje z obsevanjem, v kombinaciji s cisplatinom.
Paxene is not recommended for use in children and adolescents under 18 years.
Zdravila Paxene ni priporočljivo uporabljati pri otrocih in mladostnikih, mlajših od 18 let.
Paxene paclitaxel
Paxene paklitaksel
Paxene should be diluted in sodium chloride 9 mg/ml (0.9%) solution for injection, glucose 50 mg/ml (5%) solution for infusion, or glucose 50 mg/ml (5%) in Ringer’s solution for injection to a final concentration of 0.3 to 1.2 mg/ml.
Zdravilo Paxene je treba razredčiti do končne koncentracije 0,3 do 1,2 mg/ml v natrijevem kloridu 9 mg/ml (0,9 %) raztopini za infundiranje, glukozi 50 mg/ml (5 %) raztopini za injiciranje ali glukozi 50 mg/ml (5 %) v Ringerjevi raztopini za injiciranje..
Paxene should only be prepared and administered by personnel appropriately trained in the handling of cytotoxic agents.
Zdravilo Paxene naj pripravio in dajo samo osebe, ki so primerno izučene v postopanju z citostatični sredstvi.
Pazopanib doses up to 2000 mg have been evaluated in clinical studies.
V kliničnih študijah so ovrednotili uporabo pazopaniba v odmerkih do 2000 mg.
Pazopanib has not been studied in patients who had a history of haemoptysis, cerebral, or clinically significant gastrointestinal (GI) haemorrhage in the past 6 months.
Pri bolnikih z anamnezo izkašljevanja krvi, cerebralne krvavitve ali klinično pomembne gastrointestinalne krvavitve v zadnjih 6 mesecih uporaba pazopaniba ni raziskana.
Pazopanib is a substrate for CYP3A4, P-gp and BCRP.
Pazopanib je substrat CYP3A4, P-gp in BCRP.
Pazopanib is an orally administered, potent multi-target tyrosine kinase inhibitor (TKI) of Vascular Endothelial Growth Factor Receptors (VEGFR)-1, -2, and -3, platelet-derived growth factor (PDGFR)-α and
Je močan multitarčni zaviralec tirozin kinaznih (TKI; “tyrosine kinase inhibitor”) receptorjev za žilni endotelijski rastni faktor (VEGFR; “Vascular Endothelial Growth Factor Receptors”)-1, -2 in -3, trombocitni rastni faktor (PDGFR; “platelet- derived growth factor”)-α in –β, ter receptorje za faktor matičnih celic (“stem cell factor receptor”; (c- KIT).
Pazopanib is not recommended in patients with severe hepatic impairment (total bilirubin > 3 x ULN regardless of any level of ALT) (see section 4.2 and 5.2).
Pri bolnikih s hudo okvaro jeter (celokupni bilirubin > 3-kratna ZMN ne glede na vrednost ALT) uporaba pazopaniba ni priporočljiva (glejte poglavji 4.2 in 5.2).
Pazopanib may have a greater impact on SN- 38 disposition in subjects with the UGT1A1*28 polymorphism relative to subjects with the wild-type allele.
Pazopanib pri osebah s polimorfizmom UGT1A1*28 morda bolj vpliva na odstranjevanje SN-38 kot pri osebah z divjim tipom alela.
Pazopanib resulted in an increase of approximately 30 % in the mean AUC and Cmax of midazolam (CYP3A4 probe substrate) and increases of 33 % to 64 % in the ratio of dextrometrophan to dextrophan concentrations in the urine after oral administration of dextromethorphan (CYP2D6 probe substrate).
Pri sočasni uporabi pazopaniba sta se srednji vrednosti AUC in Cmax midazolama (preiskovani substrat za CYP3A4) povečali za približno 30 %, razmerje koncentracij dekstrometrofana in dekstrofana v urinu po peroralni uporabi dekstrometorfana (preiskovani substrat za CYP2D6) pa se je povečalo za od 33 % do 64 %.
Pazopanib should be discontinued if the patient develops nephrotic syndrome.
V primeru pojava nefrotskega sindroma je treba zdravljenje s pazopanibom prekiniti.
Pazopanib should be discontinued if there is evidence of hypertensive crisis or if hypertension is severe and persists despite anti-hypertensive therapy and pazopanib dose reduction.
Zdravljenje s pazopanibom je treba prekiniti v primeru hipertenzivne krize ali če je hipertenzija huda in traja kljub antihipertenzivnemu zdravljenju in znižanju odmerka pazopaniba.
Pazopanib should be discontinued in patients with wound dehiscence.
Pri bolnikih, pri katerih se rana ponovno odpre, je treba zdravljenje s pazopanibom prekiniti.
Pazopanib should be taken without food, at least one hour before or two hours after a meal (see section 5.2).
Bolnik mora pazopanib jemati brez hrane, vsaj eno uro pred ali dve uri po jedi (glejte poglavje 5.2).
Pazopanib should be used with caution in patients with a history of QT interval prolongation, in patients taking antiarrhythmics or other medicinal products that may prolong QT interval and those with relevant pre-existing cardiac disease.
Pri bolnikih, ki so kdaj že imeli težave s podaljšanjem intervala Q-T, pri bolnikih, ki se zdravijo z zdravili za zdravljenje srčnih aritmij ali drugimi zdravili, ki lahko podaljšajo interval Q-T, ter bolnikih, ki imajo relevantne bolezni srca, je treba pazopanib uporabljati previdno.
Pazopanib should not be used during pregnancy unless the clinical condition of the women requires treatment with pazopanib.
Pazopanib se med nosečnostjo ne sme uporabljati, razen če klinično stanje bolnice zahteva zdravljenje s pazopanibom.
Pazopanib should not be used in children younger than 2 years of age because of safety concerns on organ growth and maturation (see section 4.4 and 5.3).
Pazopaniba se ne sme uporabljati pri otrocih, mlajših od 2 let, ker obstajajo pomisleki glede varnosti, kar zadeva rast in dozorevanje organov (glejte poglavji 4.4 in 5.3).
PBA is a condition where damage to certain areas of the brain results in sudden and uncontrollable episodes of crying or laughing that do not relate to the patient’s real emotional state.
PBP je bolezen, pri kateri se zaradi poškodb nekaterih delov možganov pojavijo nenadne epizode joka ali smeha, ki jih ni mogoče nadzorovati in niso povezane z bolnikovim dejanskim čustvenim stanjem.
PBA is a neurological condition characterized by involuntary and uncontrollable episodes of laughing and/or crying, which don’t match your emotional state or mood.
PBP je nevrološka bolezen, za katero so značilne nehotene in nekontrolirane epizode smejanja in/ali joka, ki ne ustrezajo vašemu čustvenemu stanju ali razpoloženju.
PBA undergoes β-oxidation to PAA, which is conjugated with glutamine in the liver and in the kidney through the enzyme phenylacetyl-CoA: Lglutamine- N-acetyltransferase to form PAGN.
PBA se pretovri v PAA z β-oksidacijo, nato konjugira z glutaminom v jetrih in ledvicah prek encima fenilacetil KoA: L-glutamin-N-acetiltransferaza, pri čemer nastane PAGN.
PBO + DMAR D
+ DMARD
PBO + DMARD
+ DMARD
Pbo/PR48: placebo for 16 weeks in combination with peginterferon alfa-2a and ribavirin for 48 weeks
Pbo/PR48: jemanje placeba v času 16 tednov, v kombinaciji s peginterferonom alfa-2a in ribavirinom v času 48 tednov.
Pbo/PR: placebo for 12 weeks with peginterferon alfa-2a and ribavirin for 48 weeks
Pbo/PR: placebo 12 tednov in peginterferon alfa-2a in ribavirin 48 tednov
PBPC mobilisation in normal donors
Izplavljanje PBPC pri zdravih dajalcih
PBPC mobilisation in normal donors
Izplavljanje PBPC pri zdravih darovalcih
PBPC mobilisation in normal donors
Mobilizacija PBPC pri normalnih darovalcih
PC:
placebo
PC: [outer packaging only] SN: [outer packaging only] NN: [outer packaging only]
PC: [samo na zunanji ovojnini] SN: [samo na zunanji ovojnini] NN: [samo na zunanji ovojnini]